European Commission: Lundbeck and other Pharmaceutical Companies fined for delaying Market Entry of Generic Medicines through pay-for-delay Agreements* On 19 June 2013, the European Commission (the Commission) imposed a fine on the Danish pharmaceutical company Lundbeck and a number of generic companies (notably Merck KGaA/Generics UK (Generics UK is now part of Mylan), Arrow (now part of Actavis), Alpharma (now part of Zoetis), and Ranbaxy) for delaying the market entry of generic citalopram medicines through pay-for-delay agreements. The Commission
The EU Commission fines pharmaceutical companies for delaying market entry of generic medicines through pay-for-delay agreements (Lundbeck)
Access to this article is restricted to subscribers
Already Subscribed? Sign-in
Access to this article is restricted to subscribers.
Read one article for free
Sign-up to read this article for free and discover our services.